Business
Incannex Healthcare Authorizes $20 Million Share Repurchase Program
MELBOURNE, Australia and NEW YORK, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company developing innovative combination therapies for high-impact conditions, today announced that its Board of Directors has authorized a share repurchase program (the “Repurchase Program”) for up to $20 million of the Company’s outstanding shares of common stock (“Common Stock”). Under the Repurchase Program, the Compan
About this update from Incannex Healthcare Inc.
[{"type":"image","alt":"Incannex Healthcare","displaySize":"","headline":null,"caption":"Incannex Healthcare","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":50,"url":"https://media.zenfs.com/en/globenewswire.com/27f6059234ed425fa359634ca773e7f7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/JtZ_G8jXkVENc6BFL9UpGQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTcwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/27f6059234ed425fa359634ca773e7f7","width":300,"height":50}},"lazy":false},{"type":"text","content":"MELBOURNE, Australia and NEW YORK, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company developing innovative combination therapies for high-impact conditions, today announced that its Board of Directors has authorized a share repurchase program (the “Repurchase Program”) for up to $20 million of the Company’s outstanding shares of common stock (“Common Stock”).","length":459,"tagName":"p"},{"type":"text","content":"Under the Repurchase Program, the Company may repurchase shares of Common Stock through open market purchases, privately negotiated transactions, accelerated share repurchase arrangements, or other methods permitted under applicable securities laws, including under Rule 10b5-1 trading plans and in compliance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended.","length":378,"tagName":"p"},{"type":"text","content":"The timing and amount of any repurchases will depend on market conditions, available capital resources, and other factors.","length":122,"tagName":"p"},{"type":"text","content":"Incannex Healthcare President and CEO Joel Latham commented, “The approval of this $20 million repurchase program reflects our confidence in the strength of our pipeline, the resilience of our strategy, and the opportunities ahead. We believe the current market valuation does not accurately reflect the significant progress we have made across our clinical programs. This initiative allows us to act decisively, strengthen our capital management strategy, and potentially enhance long-term value creation for shareholders.”","length":524,"tagName":"p"},{"type":"text","content":"The Repurchase Program reflects Incannex’s commitment to driving sustainable shareholder value while maintaining discipline in capital ...